Alteogen’s researchers have many years of R&D and commercialization experiences in biologics.
Alteogen has been developing its own cell lines with high expression, efficient process (upstream and downstream), and optimized analysis methods for monoclonal antibody biosimilars.


Based on long and rich experiences, Alteogen has quickly developed two high quality biosimilars utilizing its own production processes, including cultivation and purification. Such processes ensure that Alteogen’s biosimilars would demonstrate “comparability” to the original biologics.